In FLAIR trial (18), non-peglyated G-CSF (as per standard dosing) for days 7 to 13 was recommended for all subsequent cycles of rituximab for participants who have had to have a previous dose delay due to neutropenia. The gene discussed is CSF3; the disease is Decreased total neutrophil count.